ibrutinib,zanubrutinib
beigene,abbvie,janssen
['alpine', 'beigene']
the final progression-free survival (pfs) analysis of our alpine trial has been published in and we're presenting the data today in a late-breaking session at #ash22. 
Formerly @BeiGeneUSA, we're transforming the biotech industry, creating impactful medicines for patients globally. Community guidelines: https://t.co/bZCHuaXk0s